Biosimilars Market Research Report - Forecast till 2032

Biosimilars Market Research Report Information By Product (Recombinant Non-Glycosylated Proteins, Recombinant Glycosylated Proteins, Recombinant Peptides), By Application (Oncology, Chronic Diseases, Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Infectious Diseases, Others), By End Users (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Forecast Till 2032

ID: MRFR/LS/0821-HCR | 95 Pages | Author: Rahul Gotadki | March 2024         

Table of Contents

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Primary Research

3.3. Secondary Research

3.4. Market Size Estimation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

6. GLOBAL BIOSIMILARS MARKET, BY PRODUCT

6.1. Overview

6.2. Recombinant Non-Glycosylated Proteins

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.2.1. Human Growth Hormone (RHGH)

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.2.2. Granulocyte Colony-Stimulating Factor (Filgrastim)

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.2.3. Insulin

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.2.4. Interferons

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3. Recombinant Glycosylated Proteins

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3.1. Erythropoietin (EPO)

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3.2. Monoclonal Antibodies (MABS)

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3.3. Follitropin

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4. Recombinant Peptides

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4.1. Glucagon

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4.2. Calcitonin

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7. GLOBAL BIOSIMILARS MARKET, BY APPLICATIONS

7.1. Overview

7.2. Oncology

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3. Chronic Diseases

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.4. Autoimmune Diseases

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.5. Blood Disorders

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.6. Growth Hormone Deficiency

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.7. Infectious Diseases

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.8. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8. GLOBAL BIOSIMILARS MARKET, BY END USER

8.1. Overview

8.2. Hospitals and Clinics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.3. Research Institutes

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.4. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9. GLOBAL BIOSIMILARS MARKET, BY REGION

9.1. Overview

9.2. Americas

9.2.1. North America

9.2.1.1. US

9.2.1.2. Canada

9.2.2. Latin America

9.3. Europe

9.3.1. Western Europe

9.3.1.1. Germany

9.3.1.2. France

9.3.1.3. Italy

9.3.1.4. Spain

9.3.1.5. UK

9.3.1.6. Rest of Western Europe

9.3.2. Eastern Europe

9.4. Asia-Pacific

9.4.1. Japan

9.4.2. China

9.4.3. India

9.4.4. Australia

9.4.5. South Korea

9.4.6. Rest of Asia-Pacific

9.5. Middle East & Africa

9.5.1. Middle East

9.5.2. Africa

10. COMPANY LANDSCAPE

10.1. Overview

10.2. Competitive Analysis

10.3. Market Share Analysis

10.4. Major Growth Strategy in the Global Biosimilars Market

10.5. Competitive Benchmarking

10.6. Leading Players in Terms of Number of Developments in the Global Biosimilars Market

10.7. Key developments and Growth Strategies

10.7.1. Product Launch/Service Deployment

10.7.2. Mergers and Acquisitions

10.7.3. Joint Ventures

10.8. Major Players Financial Matrix & Market Ratio

10.8.1. Sales & Operating Income 2020

10.8.2. Major Players R&D Expenditure 2020

10.9. Major Players Capital Market Ratio

11. COMPANY PROFILES

11.1. Pfizer

11.1.1. Company Overview

11.1.2. Product Overview

11.1.3. Financial Overview

11.1.4. Key Developments

11.1.5. SWOT Analysis

11.1.6. Key Strategies

11.2. Sandoz International

11.2.1. Company Overview

11.2.2. Product Overview

11.2.3. Financial Overview

11.2.4. Key Developments

11.2.5. SWOT Analysis

11.2.6. Key Strategies

11.3. Teva Pharmaceuticals

11.3.1. Company Overview

11.3.2. Product Overview

11.3.3. Financial Overview

11.3.4. Key Developments

11.3.5. SWOT Analysis

11.3.6. Key Strategies

11.4. Amgen, Inc.

11.4.1. Company Overview

11.4.2. Product Overview

11.4.3. Financial Overview

11.4.4. Key Developments

11.4.5. SWOT Analysis

11.4.6. Key Strategies

11.5. Biocon

11.5.1. Company Overview

11.5.2. Product Overview

11.5.3. Financial Overview

11.5.4. Key Developments

11.5.5. SWOT Analysis

11.5.6. Key Strategies

11.6. Dr. Reddy’s Laboratories

11.6.1. Company Overview

11.6.2. Product Overview

11.6.3. Financial Overview

11.6.4. Key Developments

11.6.5. SWOT Analysis

11.6.6. Key Strategies

11.7. Celltrion

11.7.1. Company Overview

11.7.2. Product Overview

11.7.3. Financial Overview

11.7.4. Key Developments

11.7.5. SWOT Analysis

11.7.6. Key Strategies

11.8. Samsung Biologics

11.8.1. Company Overview

11.8.2. Product Overview

11.8.3. Financial Overview

11.8.4. Key Developments

11.8.5. SWOT Analysis

11.8.6. Key Strategies

11.9. Eli Lily & Company

11.9.1. Company Overview

11.9.2. Product Overview

11.9.3. Financial Overview

11.9.4. Key Developments

11.9.5. SWOT Analysis

11.9.6. Key Strategies

11.10. Hospira Inc.

11.10.1. Company Overview

11.10.2. Product Overview

11.10.3. Financial Overview

11.10.4. Key Developments

11.10.5. SWOT Analysis

11.10.6. Key Strategies

11.11. Actavis, Inc.

11.12. Cipla Ltd

11.13. Stada Arzneimittel Ag

11.14. Mylan, Inc.

11.15. Others

12. APPENDIX

12.1. References

12.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL BIOSIMILARS MARKET SYNOPSIS, 2020-2027

TABLE 2 GLOBAL BIOSIMILARS MARKET ESTIMATES & FORECAST, 2020-2027 (USD MILLION)

TABLE 3 GLOBAL BIOSIMILARS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)

TABLE 4 GLOBAL BIOSIMILARS MARKET, BY APPLICATIONS, 2020-2027 (USD MILLION)

TABLE 5 GLOBAL BIOSIMILARS MARKET, BY END USERS, 2020-2027 (USD MILLION)

TABLE 6 GLOBAL BIOSIMILARS MARKET, BY REGION, 2020-2027 (USD MILLION)

TABLE 7 NORTH AMERICA: BIOSIMILARS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)

TABLE 8 NORTH AMERICA: BIOSIMILARS MARKET, BY APPLICATIONS, 2020-2027 (USD MILLION)

TABLE 9 NORTH AMERICA: BIOSIMILARS MARKET, BY END USERS, 2020-2027 (USD MILLION)

TABLE 10 US: BIOSIMILARS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)

TABLE 11 US: BIOSIMILARS MARKET, BY APPLICATIONS, 2020-2027 (USD MILLION)

TABLE 12 US: BIOSIMILARS MARKET, BY END USERS, 2020-2027 (USD MILLION)

TABLE 13 CANADA: BIOSIMILARS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)

TABLE 14 CANADA: BIOSIMILARS MARKET, BY APPLICATIONS, 2020-2027 (USD MILLION)

TABLE 15 CANADA: BIOSIMILARS MARKET, BY END USERS, 2020-2027 (USD MILLION)

TABLE 16 LATIN AMERICA: BIOSIMILARS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)

TABLE 17 LATIN AMERICA: BIOSIMILARS MARKET, BY APPLICATIONS, 2020-2027 (USD MILLION)

TABLE 18 LATIN AMERICA: BIOSIMILARS MARKET, BY END USERS, 2020-2027 (USD MILLION)

TABLE 19 EUROPE: BIOSIMILARS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)

TABLE 20 EUROPE: BIOSIMILARS MARKET, BY APPLICATIONS, 2020-2027 (USD MILLION)

TABLE 21 EUROPE: BIOSIMILARS MARKET, BY END USERS, 2020-2027 (USD MILLION)

TABLE 22 WESTERN EUROPE: BIOSIMILARS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)

TABLE 23 WESTERN EUROPE: BIOSIMILARS MARKET, BY APPLICATIONS, 2020-2027 (USD MILLION)

TABLE 24 WESTERN EUROPE: BIOSIMILARS MARKET, BY END USERS E, 2020-2027 (USD MILLION)

TABLE 25 EASTERN EUROPE: BIOSIMILARS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)

TABLE 26 EASTERN EUROPE: BIOSIMILARS MARKET, BY APPLICATIONS, 2020-2027 (USD MILLION)

TABLE 27 EASTERN EUROPE: BIOSIMILARS MARKET, BY END USERS, 2020-2027 (USD MILLION)

TABLE 28 ASIA-PACIFIC: BIOSIMILARS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)

TABLE 29 ASIA-PACIFIC: BIOSIMILARS MARKET, BY APPLICATIONS, 2020-2027 (USD MILLION)

TABLE 30 ASIA-PACIFIC: BIOSIMILARS MARKET, BY END USERS, 2020-2027 (USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA: BIOSIMILARS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA: BIOSIMILARS MARKET, BY APPLICATIONS, 2020-2027 (USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA: BIOSIMILARS MARKET, BY END USERS, 2020-2027 (USD MILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE OF THE GLOBAL BIOSIMILARS MARKET

FIGURE 3 MARKET DYNAMICS OF THE GLOBAL BIOSIMILARS MARKET

FIGURE 4 GLOBAL BIOSIMILARS MARKET SHARE, BY PRODUCT, 2020 (%)

FIGURE 5 GLOBAL BIOSIMILARS MARKET SHARE, BY APPLICATIONS, 2020 (%)

FIGURE 6 GLOBAL BIOSIMILARS MARKET SHARE, BY END USERS, 2020 (%)

FIGURE 7 GLOBAL BIOSIMILARS MARKET SHARE, BY REGION, 2020 (%)

FIGURE 8 AMERICAS: BIOSIMILARS MARKET SHAR,E BY REGION, 2020 (%)

FIGURE 9 NORTH AMERICA: BIOSIMILARS MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 10 EUROPE: BIOSIMILARS MARKET SHARE, BY REGION, 2020 (%)

FIGURE 11 WESTERN EUROPE: BIOSIMILARS MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 12 ASIA-PACIFIC: BIOSIMILARS MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 13 MIDDLE EAST & AFRICA: BIOSIMILARS MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 14 GLOBAL BIOSIMILARS MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

FIGURE 15 PFIZER: KEY FINANCIALS

FIGURE 16 PFIZER: SEGMENTAL REVENUE

FIGURE 17 PFIZER: REGIONAL REVENUE

FIGURE 18 SANDOZ INTERNATIONAL: KEY FINANCIALS

FIGURE 19 SANDOZ INTERNATIONAL: SEGMENTAL REVENUE

FIGURE 20 SANDOZ INTERNATIONAL: REGIONAL REVENUE

FIGURE 21 AMGEN, INC.: KEY FINANCIALS

FIGURE 22 AMGEN, INC.: SEGMENTAL REVENUE

FIGURE 23 AMGEN, INC.: REGIONAL REVENUE

FIGURE 24 TEVA PHARMACEUTICALS: KEY FINANCIALS

FIGURE 25 TEVA PHARMACEUTICALS: SEGMENTAL REVENUE

FIGURE 26 TEVA PHARMACEUTICALS: REGIONAL REVENUE

FIGURE 27 BIOCON: KEY FINANCIALS

FIGURE 28 BIOCON: SEGMENTAL REVENUE

FIGURE 29 BIOCON: REGIONAL REVENUE

FIGURE 30 DR. REDDY’S LABORATORIES: KEY FINANCIALS

FIGURE 31 DR. REDDY’S LABORATORIES: SEGMENTAL REVENUE

FIGURE 32 DR. REDDY’S LABORATORIES: REGIONAL REVENUE

FIGURE 33 CELLTRION: KEY FINANCIALS

FIGURE 34 CELLTRION: SEGMENTAL REVENUE

FIGURE 35 CELLTRION: REGIONAL REVENUE

FIGURE 36 SAMSUNG BIOLOGICS: KEY FINANCIALS

FIGURE 37 SAMSUNG BIOLOGICS: SEGMENTAL REVENUE

FIGURE 38 SAMSUNG BIOLOGICS: REGIONAL REVENUE

FIGURE 39 ELI LILY & COMPANY: KEY FINANCIALS

FIGURE 40 ELI LILY & COMPANY: SEGMENTAL REVENUE

FIGURE 41 ELI LILY & COMPANY: REGIONAL REVENUE

FIGURE 42 HOSPIRA INC.: KEY FINANCIALS

FIGURE 43 HOSPIRA INC.: SEGMENTAL REVENUE

FIGURE 44 HOSPIRA INC.: REGIONAL REVENUE

FIGURE 45 ACTAVIS, INC.: KEY FINANCIALS

FIGURE 46 ACTAVIS, INC.: SEGMENTAL REVENUE

FIGURE 47 ACTAVIS, INC.: REGIONAL REVENUE

FIGURE 48 CIPLA LTD.: KEY FINANCIALS

FIGURE 49 CIPLA LTD.: SEGMENTAL REVENUE

FIGURE 50 CIPLA LTD.: REGIONAL REVENUE

FIGURE 51 STADA ARZNEIMITTEL AG: KEY FINANCIALS

FIGURE 52 STADA ARZNEIMITTEL AG: SEGMENTAL REVENUE

FIGURE 53 STADA ARZNEIMITTEL AG: REGIONAL REVENUE

FIGURE 54 MYLAN, INC.: KEY FINANCIALS

FIGURE 55 MYLAN, INC.: SEGMENTAL REVENUE

FIGURE 56 MYLAN, INC.: REGIONAL REVENUE

Market Segmentation for Biosimilars Market


Biosimilars Product Outlook (USD Billion, 2018-2030)




  • Recombinant Non-Glycosylated Proteins




    • Human Growth Hormone (RHGH)




    • Granulocyte Colony-Stimulating Factor (Filgrastim)




    • Insulin




    • Interferons






  • Recombinant Glycosylated Proteins




    • Erythropoietin (EPO)




    • Monoclonal Antibodies (MABS)




    • Follitropin






  • Recombinant Peptides




    • Glucagon




    • Calcitonin






Biosimilars Applications Outlook (USD Billion, 2018-2030)




  • Oncology




  • Chronic Diseases




  • Autoimmune Diseases




  • Blood Disorders




  • Growth Hormone Deficiency




  • Infectious Diseases




  • Others




Biosimilars End User Outlook (USD Billion, 2018-2030)




  • Hospital Pharmacies




  • Retail Pharmacies




  • Online Pharmacies




Biosimilars Regional Outlook (USD Billion, 2018-2030)




  • North America Outlook (USD Billion, 2018-2030)




    • North America Biosimilars by Product




      • Recombinant Non-Glycosylated Proteins




        • Human Growth Hormone (RHGH)




        • Granulocyte Colony-Stimulating Factor (Filgrastim)




        • Insulin




        • Interferons






      • Recombinant Glycosylated Proteins




        • Erythropoietin (EPO)




        • Monoclonal Antibodies (MABS)




        • Follitropin






      • Recombinant Peptides




        • Glucagon




        • Calcitonin








    • North America Biosimilars by Applications 




      • Oncology




      • Chronic Diseases




      • Autoimmune Diseases




      • Blood Disorders




      • Growth Hormone Deficiency




      • Infectious Diseases




      • Others






    • North America Biosimilars by End User




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Pharmacies






    • US Outlook (USD Billion, 2018-2030)




    • US Biosimilars by Product




      • Recombinant Non-Glycosylated Proteins




        • Human Growth Hormone (RHGH)




        • Granulocyte Colony-Stimulating Factor (Filgrastim)




        • Insulin




        • Interferons






      • Recombinant Glycosylated Proteins




        • Erythropoietin (EPO)




        • Monoclonal Antibodies (MABS)




        • Follitropin






      • Recombinant Peptides




        • Glucagon




        • Calcitonin








    • US Biosimilars by Applications 




      • Oncology




      • Chronic Diseases




      • Autoimmune Diseases




      • Blood Disorders




      • Growth Hormone Deficiency




      • Infectious Diseases




      • Others






    • US Biosimilars by End User




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Pharmacies






    • Canada Outlook (USD Billion, 2018-2030)




    • Canada Biosimilars by Product




      • Recombinant Non-Glycosylated Proteins




        • Human Growth Hormone (RHGH)




        • Granulocyte Colony-Stimulating Factor (Filgrastim)




        • Insulin




        • Interferons






      • Recombinant Glycosylated Proteins




        • Erythropoietin (EPO)




        • Monoclonal Antibodies (MABS)




        • Follitropin






      • Recombinant Peptides




        • Glucagon




        • Calcitonin








    • Canada Biosimilars by Applications 




      • Oncology




      • Chronic Diseases




      • Autoimmune Diseases




      • Blood Disorders




      • Growth Hormone Deficiency




      • Infectious Diseases




      • Others






    • Canada Biosimilars by End User




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Pharmacies








  • Europe Outlook (USD Billion, 2018-2030)




    • Europe Biosimilars by Product




      • Recombinant Non-Glycosylated Proteins




        • Human Growth Hormone (RHGH)




        • Granulocyte Colony-Stimulating Factor (Filgrastim)




        • Insulin




        • Interferons






      • Recombinant Glycosylated Proteins




        • Erythropoietin (EPO)




        • Monoclonal Antibodies (MABS)




        • Follitropin






      • Recombinant Peptides




        • Glucagon




        • Calcitonin








    • Europe Biosimilars by Applications 




      • Oncology




      • Chronic Diseases




      • Autoimmune Diseases




      • Blood Disorders




      • Growth Hormone Deficiency




      • Infectious Diseases




      • Others






    • Europe Biosimilars by End User




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Pharmacies






    • Germany Outlook (USD Billion, 2018-2030)




    • Germany Biosimilars by Product




      • Recombinant Non-Glycosylated Proteins




        • Human Growth Hormone (RHGH)




        • Granulocyte Colony-Stimulating Factor (Filgrastim)




        • Insulin




        • Interferons






      • Recombinant Glycosylated Proteins




        • Erythropoietin (EPO)




        • Monoclonal Antibodies (MABS)




        • Follitropin






      • Recombinant Peptides




        • Glucagon




        • Calcitonin








    • Germany Biosimilars by Applications 




      • Oncology




      • Chronic Diseases




      • Autoimmune Diseases




      • Blood Disorders




      • Growth Hormone Deficiency




      • Infectious Diseases




      • Others






    • Germany Biosimilars by End User




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Pharmacies






    • France Outlook (USD Billion, 2018-2030)




    • France Biosimilars by Product




      • Recombinant Non-Glycosylated Proteins




        • Human Growth Hormone (RHGH)




        • Granulocyte Colony-Stimulating Factor (Filgrastim)




        • Insulin




        • Interferons






      • Recombinant Glycosylated Proteins




        • Erythropoietin (EPO)




        • Monoclonal Antibodies (MABS)




        • Follitropin






      • Recombinant Peptides




        • Glucagon




        • Calcitonin








    • France Biosimilars by Applications 




      • Oncology




      • Chronic Diseases




      • Autoimmune Diseases




      • Blood Disorders




      • Growth Hormone Deficiency




      • Infectious Diseases




      • Others






    • France Biosimilars by End User




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Pharmacies






    • UK Outlook (USD Billion, 2018-2030)




    • UK Biosimilars by Product




      • Recombinant Non-Glycosylated Proteins




        • Human Growth Hormone (RHGH)




        • Granulocyte Colony-Stimulating Factor (Filgrastim)




        • Insulin




        • Interferons






      • Recombinant Glycosylated Proteins




        • Erythropoietin (EPO)




        • Monoclonal Antibodies (MABS)




        • Follitropin






      • Recombinant Peptides




        • Glucagon




        • Calcitonin








    • UK Biosimilars by Applications 




      • Oncology




      • Chronic Diseases




      • Autoimmune Diseases




      • Blood Disorders




      • Growth Hormone Deficiency




      • Infectious Diseases




      • Others






    • UK Biosimilars by End User




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Pharmacies






    • Italy Outlook (USD Billion, 2018-2030)




    • Italy Biosimilars by Product




      • Recombinant Non-Glycosylated Proteins




        • Human Growth Hormone (RHGH)




        • Granulocyte Colony-Stimulating Factor (Filgrastim)




        • Insulin




        • Interferons






      • Recombinant Glycosylated Proteins




        • Erythropoietin (EPO)




        • Monoclonal Antibodies (MABS)




        • Follitropin






      • Recombinant Peptides




        • Glucagon




        • Calcitonin








    • Italy Biosimilars by Applications 




      • Oncology




      • Chronic Diseases




      • Autoimmune Diseases




      • Blood Disorders




      • Growth Hormone Deficiency




      • Infectious Diseases




      • Others






    • Italy Biosimilars by End User




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Pharmacies






    • Spain Outlook (USD Billion, 2018-2030)




    • Spain Biosimilars by Product




      • Recombinant Non-Glycosylated Proteins




        • Human Growth Hormone (RHGH)




        • Granulocyte Colony-Stimulating Factor (Filgrastim)




        • Insulin




        • Interferons






      • Recombinant Glycosylated Proteins




        • Erythropoietin (EPO)




        • Monoclonal Antibodies (MABS)




        • Follitropin






      • Recombinant Peptides




        • Glucagon




        • Calcitonin








    • Spain Biosimilars by Applications 




      • Oncology




      • Chronic Diseases




      • Autoimmune Diseases




      • Blood Disorders




      • Growth Hormone Deficiency




      • Infectious Diseases




      • Others






    • Spain Biosimilars by End User




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Pharmacies






    • Rest Of Europe Outlook (USD Billion, 2018-2030)




    • Rest Of Europe Biosimilars by Product




      • Recombinant Non-Glycosylated Proteins




        • Human Growth Hormone (RHGH)




        • Granulocyte Colony-Stimulating Factor (Filgrastim)




        • Insulin




        • Interferons






      • Recombinant Glycosylated Proteins




        • Erythropoietin (EPO)




        • Monoclonal Antibodies (MABS)




        • Follitropin






      • Recombinant Peptides




        • Glucagon




        • Calcitonin








    • Rest of Europe Biosimilars by Applications 




      • Oncology




      • Chronic Diseases




      • Autoimmune Diseases




      • Blood Disorders




      • Growth Hormone Deficiency




      • Infectious Diseases




      • Others






    • Rest of Europe Biosimilars by End User




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Pharmacies








  • Asia-Pacific Outlook (USD Billion, 2018-2030)




    • Asia-Pacific Biosimilars by Product




      • Recombinant Non-Glycosylated Proteins




        • Human Growth Hormone (RHGH)




        • Granulocyte Colony-Stimulating Factor (Filgrastim)




        • Insulin




        • Interferons






      • Recombinant Glycosylated Proteins




        • Erythropoietin (EPO)




        • Monoclonal Antibodies (MABS)




        • Follitropin






      • Recombinant Peptides




        • Glucagon




        • Calcitonin








    • Asia-Pacific Biosimilars by Applications 




      • Oncology




      • Chronic Diseases




      • Autoimmune Diseases




      • Blood Disorders




      • Growth Hormone Deficiency




      • Infectious Diseases




      • Others






    • Asia-Pacific Biosimilars by End User




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Pharmacies






    • China Outlook (USD Billion, 2018-2030)




    • China Biosimilars by Product




      • Recombinant Non-Glycosylated Proteins




        • Human Growth Hormone (RHGH)




        • Granulocyte Colony-Stimulating Factor (Filgrastim)




        • Insulin




        • Interferons






      • Recombinant Glycosylated Proteins




        • Erythropoietin (EPO)




        • Monoclonal Antibodies (MABS)




        • Follitropin






      • Recombinant Peptides




        • Glucagon




        • Calcitonin








    • China Biosimilars by Applications 




      • Oncology




      • Chronic Diseases




      • Autoimmune Diseases




      • Blood Disorders




      • Growth Hormone Deficiency




      • Infectious Diseases




      • Others






    • China Biosimilars by End User




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Pharmacies






    • Japan Outlook (USD Billion, 2018-2030)




    • Japan Biosimilars by Product




      • Recombinant Non-Glycosylated Proteins




        • Human Growth Hormone (RHGH)




        • Granulocyte Colony-Stimulating Factor (Filgrastim)




        • Insulin




        • Interferons






      • Recombinant Glycosylated Proteins




        • Erythropoietin (EPO)




        • Monoclonal Antibodies (MABS)




        • Follitropin






      • Recombinant Peptides




        • Glucagon




        • Calcitonin








    • Japan Biosimilars by Applications 




      • Oncology




      • Chronic Diseases




      • Autoimmune Diseases




      • Blood Disorders




      • Growth Hormone Deficiency




      • Infectious Diseases




      • Others






    • Japan Biosimilars by End User




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Pharmacies






    • India Outlook (USD Billion, 2018-2030)




    • India Biosimilars by Product




      • Recombinant Non-Glycosylated Proteins




        • Human Growth Hormone (RHGH)




        • Granulocyte Colony-Stimulating Factor (Filgrastim)




        • Insulin




        • Interferons






      • Recombinant Glycosylated Proteins




        • Erythropoietin (EPO)




        • Monoclonal Antibodies (MABS)




        • Follitropin






      • Recombinant Peptides




        • Glucagon




        • Calcitonin








    • India Biosimilars by Applications 




      • Oncology




      • Chronic Diseases




      • Autoimmune Diseases




      • Blood Disorders




      • Growth Hormone Deficiency




      • Infectious Diseases




      • Others






    • India Biosimilars by End User




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Pharmacies






    • Australia Outlook (USD Billion, 2018-2030)




    • Australia Biosimilars by Product




      • Recombinant Non-Glycosylated Proteins




        • Human Growth Hormone (RHGH)




        • Granulocyte Colony-Stimulating Factor (Filgrastim)




        • Insulin




        • Interferons






      • Recombinant Glycosylated Proteins




        • Erythropoietin (EPO)




        • Monoclonal Antibodies (MABS)




        • Follitropin






      • Recombinant Peptides




        • Glucagon




        • Calcitonin








    • Australia Biosimilars by Applications 




      • Oncology




      • Chronic Diseases




      • Autoimmune Diseases




      • Blood Disorders




      • Growth Hormone Deficiency




      • Infectious Diseases




      • Others






    • Australia Biosimilars by End User




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Pharmacies






    • South Korea Outlook (USD Billion, 2018-2030)




    • South Korea Biosimilars by Product




      • Recombinant Non-Glycosylated Proteins




        • Human Growth Hormone (RHGH)




        • Granulocyte Colony-Stimulating Factor (Filgrastim)




        • Insulin




        • Interferons






      • Recombinant Glycosylated Proteins




        • Erythropoietin (EPO)




        • Monoclonal Antibodies (MABS)




        • Follitropin






      • Recombinant Peptides




        • Glucagon




        • Calcitonin








    • South Korea Biosimilars by Applications 




      • Oncology




      • Chronic Diseases




      • Autoimmune Diseases




      • Blood Disorders




      • Growth Hormone Deficiency




      • Infectious Diseases




      • Others






    • South Korea Biosimilars by End User




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Pharmacies






    • Rest of Asia-Pacific Outlook (USD Billion, 2018-2030)




    • Rest of Asia-Pacific Biosimilars by Product




      • Recombinant Non-Glycosylated Proteins




        • Human Growth Hormone (RHGH)




        • Granulocyte Colony-Stimulating Factor (Filgrastim)




        • Insulin




        • Interferons






      • Recombinant Glycosylated Proteins




        • Erythropoietin (EPO)




        • Monoclonal Antibodies (MABS)




        • Follitropin






      • Recombinant Peptides




        • Glucagon




        • Calcitonin








    • Rest of Asia-Pacific Biosimilars by Applications 




      • Oncology




      • Chronic Diseases




      • Autoimmune Diseases




      • Blood Disorders




      • Growth Hormone Deficiency




      • Infectious Diseases




      • Others






    • Rest of Asia-Pacific Biosimilars by End User




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Pharmacies








  • Rest of the World Outlook (USD Billion, 2018-2030)




    • Rest of the World Biosimilars by Product




      • Recombinant Non-Glycosylated Proteins




        • Human Growth Hormone (RHGH)




        • Granulocyte Colony-Stimulating Factor (Filgrastim)




        • Insulin




        • Interferons






      • Recombinant Glycosylated Proteins




        • Erythropoietin (EPO)




        • Monoclonal Antibodies (MABS)




        • Follitropin






      • Recombinant Peptides




        • Glucagon




        • Calcitonin








    • Rest of the World Biosimilars by Applications 




      • Oncology




      • Chronic Diseases




      • Autoimmune Diseases




      • Blood Disorders




      • Growth Hormone Deficiency




      • Infectious Diseases




      • Others






    • Rest of the World Biosimilars by End User




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Pharmacies






    • Middle East Outlook (USD Billion, 2018-2030)




    • Middle East Biosimilars by Product




      • Recombinant Non-Glycosylated Proteins




        • Human Growth Hormone (RHGH)




        • Granulocyte Colony-Stimulating Factor (Filgrastim)




        • Insulin




        • Interferons






      • Recombinant Glycosylated Proteins




        • Erythropoietin (EPO)




        • Monoclonal Antibodies (MABS)




        • Follitropin






      • Recombinant Peptides




        • Glucagon




        • Calcitonin








    • Middle East Biosimilars by Applications 




      • Oncology




      • Chronic Diseases




      • Autoimmune Diseases




      • Blood Disorders




      • Growth Hormone Deficiency




      • Infectious Diseases




      • Others






    • Middle East Biosimilars by End User




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Pharmacies






    • Africa Outlook (USD Billion, 2018-2030)




    • Africa Biosimilars by Product




      • Recombinant Non-Glycosylated Proteins




        • Human Growth Hormone (RHGH)




        • Granulocyte Colony-Stimulating Factor (Filgrastim)




        • Insulin




        • Interferons






      • Recombinant Glycosylated Proteins




        • Erythropoietin (EPO)




        • Monoclonal Antibodies (MABS)




        • Follitropin






      • Recombinant Peptides




        • Glucagon




        • Calcitonin








    • Africa Biosimilars by Applications 




      • Oncology




      • Chronic Diseases




      • Autoimmune Diseases




      • Blood Disorders




      • Growth Hormone Deficiency




      • Infectious Diseases




      • Others






    • Africa Biosimilars by End User




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Pharmacies






    • Latin America Outlook (USD Billion, 2018-2030)




    • Latin America Biosimilars by Product




      • Recombinant Non-Glycosylated Proteins




        • Human Growth Hormone (RHGH)




        • Granulocyte Colony-Stimulating Factor (Filgrastim)




        • Insulin




        • Interferons






      • Recombinant Glycosylated Proteins




        • Erythropoietin (EPO)




        • Monoclonal Antibodies (MABS)




        • Follitropin






      • Recombinant Peptides




        • Glucagon




        • Calcitonin








    • Latin America Biosimilars by Applications 




      • Oncology




      • Chronic Diseases




      • Autoimmune Diseases




      • Blood Disorders




      • Growth Hormone Deficiency




      • Infectious Diseases




      • Others






    • Latin America Biosimilars by End User




      • Hospital Pharmacies




      • Retail Pharmacies




      • Online Pharmacies







Leading companies partner with us for data-driven Insights.
Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response
Invalid

Research Methodology on Biosimilars Market


Introduction


The advancement in biotechnology and the increasing number of applications of biologics and biosimilars in therapeutics and diagnostics has created a need to understand the factors driving the global biosimilars market. Biosimilars are drug products similar to the originator biologic product but not an exact copy of it, developed and manufactured using recombinant DNA technology for commercial use in the marketplace. The Market Research Future (MRFR) report studies this market in detail with a focus on several factors such as market growth drivers, challenges, regional markets, and competitive landscape.


Research Objectives


The objectives of this comprehensive research are to:



  • Analyze the global biosimilars market to understand the current market situation and the growth potential in the future.

  • Analyse the regional markets for biosimilars, including North America, Europe, South America, Asia-Pacific (APAC) and the Middle East & Africa to identify the opportunities in each region.

  • Evaluate the key factors driving and restraining global biosimilars market growth.

  • Determine the technological advancements, developments and trends in the global biosimilars market.

  • Evaluate the change in customer preferences and the capacity of the industry to cope with them.

  • Study the competitive landscape and assess the strategies adopted by the leading players in the biosimilars market.


Research Methodology


Research design and approach


The study is based on the analysis of both secondary and primary data sources. Secondary data related to the biosimilars market is collected from various published sources, such as annual reports, news articles and press releases, patent applications, and recognised sources from industry publications. Primary data is collected through interviews with experts and leading industry professionals, as well as through surveys for customer and consumer treatment data about biosimilars. Additionally, data is also collected through interviews and surveys with clinicians, regulatory bodies, resellers, and distributors. The research team also conducts detailed analyses of collected data to conclude.


Primary Research


Primary research methods are used to uncover the pieces of information that cannot be determined through secondary data. Primary research involves interviewing clinical experts, medical and market researchers, key industry opinion leaders, and regulatory bodies, and holds immense importance in the market study. Through primary research, the team strives to understand and accurately reflect and assess the state of the biosimilars market.


Secondary Research


Secondary sources, such as Annual Reports, Medical Journals, and Economic Forecasts, are referred to analyse the industry trends and to enable a comprehensive understanding of the biosimilars market. All of these sources are constantly monitored to help verify, update, and extrapolate data, to offer accurate and up-to-date market intelligence. The team also features industry experts, who constantly monitor and analyze the pharmaceuticals industry in various regions.


Market Segmentation


The market of biosimilars is segmented based on type into monoclonal antibodies and other biosimilars (recombinant proteins, hormones, interferons, and insulin). Other biosimilars are further segmented into epoetin alfa, filgrastim, granulocyte growth factor, and interferon among others. Based on therapeutic areas, the market is segmented into oncology, immunology, a blood disorder, cardiovascular, endocrinology and other therapeutic areas. Based on end users, the market is segmented into hospitals, speciality clinics, retail pharmacies and online pharmacies.


Data Triangulation


Data triangulation is used to validate the results of data collection and the uncertainty associated with each estimate. Different combinations of data from multiple sources are used to develop and verify the market estimates. Also, the weighted average of the original sizes and the expected growth from the same sources are used to corroborate the market estimations.


Conclusion


This comprehensive research methodology provides systematic and thorough information about the current biosimilar market and the forces shaping it. It covers all the major facets of the global biosimilars market and helps to create an in-depth understanding of the market. The research reveals that the biosimilars market is expected to grow at a steady pace during the forecast period of 2023-2030. Factors such as increasing research & development activities, regulatory changes, technological advancements etc. are expected to drive the biosimilars market growth in the coming years.

Speak to Analyst